BRTX
BioRestorative Therapies, Inc.
$0.3525
-6.25%
$9.0M
No data for this timeframe.
Vol
Market Cap$9.0M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$84.5K
Inst. Activity1 buys / 0 sells
Reddit Sentiment57° Neutral
SEC Reports3
Press Releases1
Exchange Nasdaq·Sector Services-Misc Health & Allied Services, NEC·Inc. NV·CIK 0001505497·Prev Close $0.3760
Recent Activity
Jun 12, 2026
SEC
BioRestorative Therapies entered into a $1M revolving credit facility with Bowery Group LLC, bearing 12% interest and ma
8-K — Impact 6/10
May 29, 2026
SEC
BioRestorative Therapies filed an 8-K reporting the entry into new 3-year employment agreements with CEO Lance Alstodt (
8-K — Impact 6/10
May 1, 2026
SEC
BioRestorative Therapies disclosed cash bonuses for its named executive officers for fiscal year 2025, with total compen
8-K — Impact 3/10
Inst.
STATE STREET CORP — ADD
32,459 shares ($38.0K)
Inst.
VANGUARD GROUP INC — DOUBLED
88,778 shares ($127.0K)
May 26, 2026
other
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
<p align="center"><i>Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has com
Apr 15, 2026
Event
DIACOMIT
Supplemental Approval — Labeling — CAPSULE
Apr 7, 2026
Press
BioRestorative Therapies (BRTX) announced a strategic collaboration with 203 Creates, a brand strategy and marketing fir
Impact 3/10
Price Targets
Historical data — last covering-analyst action Aug 2024. No current recommendation available.
$8.00 (Aug 2024)
Current $0.3525
Low $1.00
Median $8.00
High $15.00
2 analysts
$1.00
$15.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 14, 2024 | Roth MKM | MAINTAIN | Buy → Buy |
| Jun 12, 2024 | Roth MKM | MAINTAIN | Buy → Buy |
| Aug 14, 2023 | Roth MKM | REITERATE | Buy → Buy |
| Dec 7, 2022 | Roth Capital | INITIATE | Buy |
| Sep 28, 2022 | Maxim Group | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.15 ▲ +40.0% | $-0.15 — $-0.15 | 50% YoY | 1 |
| Next Q | $-0.13 ▲ +43.5% | $-0.13 — $-0.13 | 61% YoY | 1 |
| Current FY | $-0.66 ▲ +43.6% | $-0.66 — $-0.66 | 58% YoY | 1 |
| Next FY | $-0.52 ▲ +46.4% | $-0.52 — $-0.52 | 21% YoY | 1 |
Latest Reports
BEARISH
8-K
6/10
BioRestorative Therapies entered into a $1M revolving credit facility with Bowery Group LLC, bearing 12% interest and ma
Jun 12, 2026
BEARISH
8-K
6/10
BioRestorative Therapies filed an 8-K reporting the entry into new 3-year employment agreements with CEO Lance Alstodt (
May 29, 2026
NEUTRAL
Press
3/10
BioRestorative Therapies (BRTX) announced a strategic collaboration with 203 Creates, a brand strategy and marketing fir
Apr 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| CITADEL ADVISORS LLC | $64.9K | — |
| VANGUARD FIDUCIARY TRUST CO | $10.7K | — |
| STATE STREET CORP | $8.8K | ADD |
| TD Waterhouse Canada Inc. | $1.00 | ADD |
Reddit Sentiment
57°
Neutral
Bearish
Neutral
Bullish
4 institutional holders with $84.5K total value (310,520 shares) as of 2026-Q1. Top holders: CITADEL, VANGUARD, STATE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 238,606 | $64.9K | 76.8% | — |
| 2 | VANGUARD FIDUCIARY TRUST CO | 39,452 | $10.7K | 12.7% | — |
| 3 | STATE STREET CORP | 32,459 | $8.8K | 10.5% | ADD +58.7% |
| 4 | TD Waterhouse Canada Inc. | 3 | $1.00 | 0.0% | ADD +50.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 20,459 | 32,459 | +58.7% | $38.0K | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 29,730 | 88,778 | +198.6% | $127.0K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 8,346 | 3 | -100.0% | $5.00 | 2025-Q2 |
| MORGAN STANLEY | ADD | 27,500 | 38,000 | +38.2% | $67.6K | 2025-Q1 |
| UBS Group AG | TRIM | 16,297 | 8,346 | -48.8% | $14.9K | 2025-Q1 |
| TD Waterhouse Canada Inc. | ADD | 2 | 3 | +50.0% | $5.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 17,500 | 27,500 | +57.1% | $39.3K | 2024-Q4 |
| UBS Group AG | DOUBLED | 693 | 16,297 | +2251.7% | $23.3K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
BEARISH
8-K
6/10
BioRestorative Therapies entered into a $1M revolving credit facility with Bowery Group LLC, bearing
Jun 12, 2026
BEARISH
8-K
6/10
BioRestorative Therapies filed an 8-K reporting the entry into new 3-year employment agreements with
May 29, 2026
NEUTRAL
8-K
3/10
BioRestorative Therapies disclosed cash bonuses for its named executive officers for fiscal year 202
May 1, 2026
Historical analyst distribution (last covering-analyst action Aug 2024): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2024. No current recommendation available.
$8.00 mean target (Aug 2024)
$1.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $0.3525 |
| Target Low | $1.00 |
| Target Mean | $8.00 |
| Target Median | $8.00 |
| Target High | $15.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.15 | $-0.15 | $-0.15 | 50.0% | +40.0% | 1↑ 0↓ | $0.0B | 10.4% | 1 |
| Next Q 2026-09-30 |
$-0.13 | $-0.13 | $-0.13 | 60.6% | +43.5% | 1↑ 0↓ | $0.0B | 3035.6% | 1 |
| Current FY 2026-12-31 |
$-0.66 | $-0.66 | $-0.66 | 58.2% | +43.6% | 1↑ 0↓ | $0.0B | 290.6% | 1 |
| Next FY 2027-12-31 |
$-0.52 | $-0.52 | $-0.52 | 21.2% | +46.4% | 1↑ 0↓ | $0.0B | 64.6% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.150 | |
| 7d ago | $-0.250 | +0.100 |
| 30d ago | $-0.250 | +0.100 |
| 60d ago | $0.000 | -0.150 |
| 90d ago | $0.000 | -0.150 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 14, 2024 | Roth MKM | MAINTAIN | Buy | Buy |
| Jun 12, 2024 | Roth MKM | MAINTAIN | Buy | Buy |
| Aug 14, 2023 | Roth MKM | REITERATE | Buy | Buy |
| Dec 7, 2022 | Roth Capital | INITIATE | — | Buy |
| Sep 28, 2022 | Maxim Group | INITIATE | — | Buy |
| Dec 1, 2021 | Roth Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
57°
Neutral
Bearish
Neutral
Bullish
3 mentions
1 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 27, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 27, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Feb 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 26, 2026
other
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
<p align="center"><i>Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Co
May 20, 2026
earnings_calendar
BRTX Q1 2026 Earnings Scheduled — 2026-05-20
May 13, 2026
other
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
<p align="center"><i>Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and ae
May 13, 2026
earnings_calendar
BRTX Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings_calendar
BRTX Q1 2026 Earnings Scheduled — 2026-05-12
Apr 30, 2026
other
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
<p align="center"><i>Data demonstrate progress in each of its MSC-derived programs</i></p>
Apr 23, 2026
short_volume
Short Volume: BRTX — 59.4% short (0.4M / 0.7M)
Short: 412,041 | Exempt: 2,302 | TRF Vol: 693,900 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: BRTX — 61.2% short (0.5M / 0.8M)
Short: 466,185 | Exempt: 134,865 | TRF Vol: 762,060 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: BRTX — 55.1% short (0.3M / 0.6M)
Short: 321,856 | Exempt: 375 | TRF Vol: 583,797 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
FDA
DIACOMIT
Supplemental Approval — Labeling — CAPSULE
Apr 14, 2026
short_volume
Short Volume: BRTX — 60.3% short (0.5M / 0.9M)
Short: 525,236 | Exempt: 25,800 | TRF Vol: 871,247 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
contract
BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform
<p align="center"><i>Partnership to drive brand architecture, go-to-market execution, and global launch of the Company’s product portfolio bridging bi
Apr 7, 2026
short_volume
Short Volume: BRTX — 62.4% short (0.9M / 1.4M)
Short: 903,568 | Exempt: 214,196 | TRF Vol: 1,447,027 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
other
BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
<p align="center"><i>Data showed 50% or more of patients reporting >50% improvement in key pain and function scales </i></p>
Mar 27, 2026
short_volume
Short Volume: BRTX — 59.4% short (0.9M / 1.6M)
Short: 943,449 | Exempt: 1,800 | TRF Vol: 1,588,893 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
earnings_calendar
BRTX Q4 2025 Earnings Before Market Open — 2026-03-26